HOOKIPA Entered into an Amended and Restated Collaboration and License Agreement with Gilead to Develop Arenaviral Immunotherapies for HIV
Shots:
- Hookipa to receive $15M as an initiation fee, $5M as an equity investment at a premium to the current market price along with an additional ~$30M of equity financing
- Gilead gets an exclusive right for further program development & plans to advance the program to the IND-enabling stage in 2022 to support a clinical trial of arenaviral therapeutic for HBV while HOOKIPA will be responsible to advance the HIV program upon the completion of a P-I trial
- Under the 2018 collaboration and license agreement, Hookipa received a one-time $4M preclinical milestone & Gilead got exclusive rights to Hookipa’s versatile arenaviral platform to develop immunotherapies for HIV and HBV
Ref: Globe Newswire | Image: Globe Newswire
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
